Bioavailability and bioequivalence: focus on physiological factors and variability

Area of Science:

• Pharmacology
• Drug Development
• Regulatory Science

Background:

• The EUFEPS & COST B25 conference convened to discuss bioavailability (BA) and bioequivalence (BE).
• Focus areas included physiological factors influencing drug absorption and inter-individual variability.
• The conference addressed challenges in drug absorption, pre-systemic effects, and regulatory aspects of BA/BE.

Purpose of the Study:

• To summarize key discussions from the EUFEPS & COST B25 conference on drug bioavailability and bioequivalence.
• To highlight the impact of physiological factors, food, and formulation on drug absorption.
• To address variability in bioequivalence studies and unresolved regulatory issues.

Main Methods:

• The conference involved presentations and panel sessions on drug absorption, metabolism, and regulatory science.
• Discussions integrated gastrointestinal physiology, in-vitro data, and pharmacokinetic modeling.
• Analysis of intra-subject variability in bioequivalence studies and regulatory authority perspectives (EMEA, US-FDA).

Main Results:

• Gastrointestinal complexity and site-dependent absorption significantly impact drug bioavailability.
• Food and formulation effects, along with pre-systemic metabolism, are crucial considerations.
• High intra-subject variability in bioequivalence studies presents challenges, necessitating careful study design and statistical analysis.

Conclusions:

• Understanding physiological factors and variability is essential for accurate bioavailability and bioequivalence assessments.
• Biopharmaceutical classification systems (BCS, BDDCS) and advanced modeling aid in predicting drug behavior.
• Addressing unresolved regulatory issues is critical for advancing drug development and ensuring therapeutic equivalence.